Amneal Pharmaceuticals, Inc. (AMRX) News
Filter AMRX News Items
AMRX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest AMRX News From Around the Web
Below are the latest news stories about AMNEAL PHARMACEUTICALS INC that investors may wish to consider to help them evaluate AMRX as an investment opportunity.
Amneal to Participate at Upcoming Investor ConferencesBRIDGEWATER, N.J., December 04, 2024--Amneal to Participate at Upcoming Investor Conferences |
Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 AgonistBRIDGEWATER, N.J., November 21, 2024--Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist |
Amneal Pharmaceuticals Inc (AMRX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...Amneal Pharmaceuticals Inc (AMRX) reports robust Q3 performance with significant strides in new markets and innovative product launches. |
Amneal Reports Third Quarter 2024 Financial ResultsBRIDGEWATER, N.J., November 08, 2024--Amneal Reports Third Quarter 2024 Financial Results |
Amneal Pharmaceuticals (NASDAQ:AMRX) grows 3.0% this week, taking five-year gains to 211%The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on a lighter note, a... |
Amneal Receives U.S. FDA Approval of New Drug Application for Pyridostigmine Bromide Extended-Release TabletsBRIDGEWATER, N.J., October 21, 2024--Amneal Receives U.S. FDA Approval of New Drug Application for Pyridostigmine Bromide Extended-Release Tablets |
Amneal Pharmaceuticals Inc (AMRX) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ...Amneal Pharmaceuticals Inc (AMRX) reports a 17% revenue increase and raises 2024 guidance amid key product launches and strategic developments. |
Amneal to Report Third Quarter 2024 Results on November 8, 2024BRIDGEWATER, N.J., October 08, 2024--Amneal to Report Third Quarter 2024 Results on November 8, 2024 |
Amneal and Metsera Announce Strategic Collaboration to Develop and Supply Portfolio of Next-Generation Medicines for Obesity and Metabolic DiseasesBRIDGEWATER, N.J. & NEW YORK, October 01, 2024--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company"), a global pharmaceutical company, and Metsera, Inc. ("Metsera"), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced that they have entered into a collaboration agreement to enable the efficient development and large-scale supply of a portfolio of new weight loss medicines globally. |
Amneal Launches CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules for Treatment of Parkinson’s DiseaseBRIDGEWATER, N.J., September 23, 2024--Amneal Launches CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules for Treatment of Parkinson’s Disease |